Abbreviations

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

ABI Ankle-brachial index

ACC American College of Cardiology

ACS Acute coronary syndrome

AE Adverse event

AHA American Heart Association

AIDS Acquired immune deficiency syndrome

ALT Alanine aminotransferase

AP Angina pectoris

apo B Apolipoprotein B

APOC3 Apolipoprotein C3

AST Aspartate aminotransferase

ATP Adult Treatment Panel

BMI Body mass index

BUN Blood urea nitrogen

CABG Coronary artery bypass graft

CAD Coronary artery disease

CBC Complete blood count

CEC Clinical Endpoint Committee

CHD Coronary heart disease

CHF Congestive heart failure

CI Confidence interval

CK-MB Creatine kinase-MB fraction

CrCL Creatinine clearance

CRF Case report form

CV Cardiovascular

CVD Cardiovascular disease

DHA Docosahexaenoic acid

DMC Data Monitoring Committee

EC Independent Ethics Committee

ECG Electrocardiogram

EDC Electronic data capture

eGRF Estimated glomerular filtration rate

EPA Eicosapentaenoic acid

Ethyl-EPA ethyl eicosapentaenoic acid

EU European Union

FBG Fasting blood glucose

FDA United States Food and Drug Administration

FSH Follicle-stimulating hormone

GCP Good Clinical Practice

GGT Gamma-glutamyl transferase

GMP Good Manufacturing Practice

GWAS Genome-wide association study

HbA1c Hemoglobin A1c

Hct Hematocrit

HDL-C High-density lipoprotein cholesterol

HF Heart failure

Hgb Hemoglobin

HIV Human immunodeficiency virus

HR Hazard ratio

hs-CRP High-sensitivity C-reactive protein

hsTnT High-sensitivity troponin T

HTG Hypertriglyceridemia

ICF Informed consent form

ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

IFCC International Federation of Clinical Chemistry

IMP Investigational medicinal product

IQR Interquartile range

IRB Institutional Review Board

ITT Intent-to-Treat

IWRS Interactive Web Response System

JAS Japanese Atherosclerosis Society

LBBB Left bundle branch block

LDL-C Low-density lipoprotein cholesterol

LOE Lack of efficacy

LpPLA2 Lipoprotein-associated phospholipase A2

LVH Left ventricle hypertrophy

MACE Major adverse coronary event

MI Myocardial infarction or mitral insufficiency

mITT Modified Intent-to-Treat

NCEP National Cholesterol Education Program

NGSP National Glycohemoglobin Standardization Program

NMR Nuclear magnetic resonance

NSTE-ACS Non-ST-segment elevation acute coronary syndrome

O3FA Omega-3 fatty acid

ODIS Off drug in stud y OGTT Oral glucose tolerance test

OR Odds ratio

PAD Peripheral arterial disease

PCI Percutaneous coronary intervention

PCSK9 Proprotein convertase subtilisin kexin 9

PH Proportional hazard

PI Principal Investigator

PP Per protocol

PVD Peripheral vascular disease

RBC Red blood cells

RLP-C Remnant lipoprotein cholesterol

RR Relative risk

SAE Serious adverse event

SAP Statistical Analysis Plan

SC Steering Committee

SPC Summary of Product Characteristics

SUSAR Suspected unexpected serious adverse reaction

TC Total cholesterol

TEAE Treatment-emergent adverse event

TG Triglycerides

TIA Transient Ischemic Attack

TIMI Thrombolysis In Myocardial Infarction

ULN Upper limit of normal

US United States

USPI United States Prescribing Information

VLDL-C Very low density lipoprotein cholesterol

WBC White cell blood count